Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

Small Cell Lung Cancer Extensive Stage Clinical Trial

— Acclaim-3  

Official title:

A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05703971
• Other study ID #: ONC-005
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: May 9, 2024
• Est. completion date: August 2027

Study information

• Verified date: May 2024
• Source: Genprex, Inc.
• Contact: Sr Director, Clinical Operations
• Phone: 1-877-774-GNPX
• Email: kcombs[@]genprex.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical trial will evaluate the combination of quaratusugene ozeplasmid with atezolizumab as maintenance therapy for patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC).

The study will be conducted in 2 phases, a dose selection phase (Phase 1) and a safety and efficacy evaluation phase (Phase 2).

Description:

Acclaim-3 is an open-label, multi-center, Phase 1/2 study evaluating the combination of quaratusugene ozeplasmid with atezolizumab as maintenance therapy for patients with ES-SCLC who did not develop tumor progression after receiving at least 3 cycles, and no more than 4 cycles, of induction therapy with carboplatin plus etoposide and atezolizumab.

Toxicities will be assessed by the Investigator using United States National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Serious Adverse Events and Dose Limiting Toxicities (DLTs) will be reviewed by a safety review committee.

Phase 1: In Phase 1 dose selection, patients will be enrolled in sequential cohorts treated with successively higher doses of quaratusugene ozeplasmid in combination with atezolizumab. The recommended Phase 2 dose (RP2D) of quaratusugene ozeplasmid when given in combination with atezolizumab will be identified.

Phase 2: Quaratusugene ozeplasmid in combination with atezolizumab will be further evaluated using the RP2D identified in Phase 1.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 62
• Est. completion date: August 2027
• Est. primary completion date: February 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Documented history of histologically or cytologically confirmed ES-SCLC, prior to starting treatment with the combination of atezolizumab, carboplatin, and etoposide

• Complete Response (CR), Partial Response (PR), or Stable Disease (SD) after receiving at least 3 cycles, and no more than 4 cycles, of atezolizumab, carboplatin, and etoposide.

• Eastern Cooperative Oncology Group performance status (ECOG PS) score from 0 to 1.

• Must be =28 days beyond major surgical procedures such as thoracotomy, laparotomy, or joint replacement, and must be =10 days beyond minor surgical procedures such as biopsy of subcutaneous tumors, pleuroscopy, etc., and must not have evidence of wound dehiscence, active wound infection, or comparable major residual complications of the surgery per investigator assessment.

• Asymptomatic brain metastases must meet ALL criteria of the following (a-d): a. No history of seizures in the preceding 6 months; b. Definitive treatment must be completed =21 days prior to enrollment; c. Must be off steroids administered because of brain metastases or related symptoms for =7 days; d. If had previous brain irradiation, post-treatment imaging must demonstrate stability or regression of the brain metastases.

• Absolute neutrophil count (ANC) >1500/mm3, platelet count >100,000/mm3 within =21 days.

• Adequate renal function documented by serum creatinine of =1.5 mg/dL or calculated creatinine clearance >50 ml/min within =21 days.

• Adequate hepatic function as documented by serum bilirubin <1.5 mg/dL and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =2.5 X upper limit of normal (ULN) within =21 days.

• Stable cardiac condition with a left ventricular ejection fraction =40% within =21 days.

• If female of childbearing potential (FOCBP), must have negative serum pregnancy test (serum beta-human chorionic gonadotropin [ß-hCG]) within =7 days of first dose.

• FOCBP and men who are sexually active with FOCBP must agree to use 2 forms of contraception during the study period and for 4 months following the last dose of study treatment.

• If male, must agree to no sperm donation during study treatment and for an additional 4 months following the last dose of study treatment.

• Must have voluntarily signed an informed consent in accordance with institutional policies.

Exclusion Criteria:

• Unable to tolerate atezolizumab treatment, leading to early treatment discontinuation or prolonged/frequent dosage modifications in previous atezolizumab treatment as determined by the investigator.

• Received prior gene therapy.

• Received prophylactic cranial irradiation or consolidation thoracic radiation.

• Active systemic viral, bacterial, or fungal infection(s) requiring treatment.

• Serious concurrent illness or psychological, familial, sociological, geographical, or other concomitant conditions that, in the opinion of the investigator, would not permit adequate follow-up and compliance with the study protocol.

• History of autoimmune disease requiring immunosuppression.

• History of myocardial infarction or unstable angina within =6 months.

• Known human immunodeficiency virus (HIV) infection or has active hepatitis infection.

• Female who is pregnant or breastfeeding.

Related Conditions & MeSH terms

• Lung Neoplasms
• Small Cell Lung Cancer Extensive Stage
• Small Cell Lung Carcinoma

Intervention

Biological:
• quaratusugene ozeplasmid
Quaratusugene ozeplasmid is an experimental nonviral immunogene therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, reestablishing pathways that promote cancer cell death and modulating the immune response against cancer cells.
• atezolizumab
Atezolizumab is a monoclonal antibody that belongs to a class of drugs that binds to the programmed death-receptor 1 ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions.

Locations

Country	Name	City	State
United States	Oncology_Hematology Care Clinical Trials, LLC	Cincinnati	Ohio
United States	Oncology_Hematology Care Clinical Trials, LLC	Cincinnati	Ohio
United States	Oncology_Hematology Care Clinical Trials, LLC	Cincinnati	Ohio
United States	Oncology_Hematology Care Clinical Trials, LLC	Cincinnati	Ohio
United States	Texas Oncology - DFW	Dallas	Texas
United States	Willamette Valley Cancer Institute (Oregon)	Eugene	Oregon
United States	Virginia Cancer Specialists, PC	Fairfax	Virginia
United States	Oncology_Hematology Care Clinical Trials, LLC	Fairfield	Ohio
United States	Rocky Mountain Cancer Centers, LLP	Lone Tree	Colorado
United States	Northwest Cancer Specialists, P.C.	Portland	Oregon
United States	Northwest Cancer Specialists, P.C.	Portland	Oregon
United States	Providence Cancer Institute	Portland	Oregon
United States	Washington University School of Medicine - Siteman Cancer Center	Saint Louis	Missouri
United States	Northwest Cancer Specialists, P.C.	Tigard	Oregon
United States	Texas Oncology - Northeast Texas	Tyler	Texas
United States	Northwest Cancer Specialists, P.C.	Vancouver	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Genprex, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) - Phase 1	The MTD and/or RP2D of the combination of quaratusugene ozeplasmid and atezolizumab.; Note: if a MTD is not determined, the RP2D will be selected based on all available data (safety, PK, PD, and preliminary efficacy).	First 21-days at each dose level
Primary	Progression-Free Survival Rate (PFSR) - Phase 2	PFSR at 18 weeks according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1).	18-weeks from Day 1 of maintenance therapy
Secondary	Safety Profile - Phase 1	Adverse events according to CTCAE v5.0	Approximately 6 months
Secondary	Progression-free Survival (PFS) - Phase 1 & Phase 2	PFS per RECIST 1.1. PFS is defined as time from Day 1 of maintenance therapy to disease progression or death.	Approximately 5 months
Secondary	Pharmacokinetics (PK) of Quaratusugene Ozeplasmid - Phase 1 & Phase 2	Concentration of quaratusugene ozeplasmid in whole blood samples.	First 21-day treatment cycle
Secondary	Overall Survival (OS) - Phase 1 & Phase 2	Number of months from Day 1 of maintenance therapy to the date of death.	Approximately 18 months